Sunflower Bank N.A. Purchases 25 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sunflower Bank N.A. increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 725 shares of the medical equipment provider’s stock after acquiring an additional 25 shares during the period. Sunflower Bank N.A.’s holdings in Intuitive Surgical were worth $378,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ISRG. State Street Corp increased its stake in shares of Intuitive Surgical by 1.4% in the third quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider’s stock valued at $7,393,673,000 after buying an additional 210,363 shares in the last quarter. FMR LLC grew its holdings in Intuitive Surgical by 8.3% during the 3rd quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock worth $5,389,765,000 after acquiring an additional 838,793 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Intuitive Surgical by 1.9% in the third quarter. Geode Capital Management LLC now owns 7,512,925 shares of the medical equipment provider’s stock worth $3,677,194,000 after acquiring an additional 143,440 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Intuitive Surgical by 1.8% during the third quarter. Fisher Asset Management LLC now owns 4,782,381 shares of the medical equipment provider’s stock worth $2,349,441,000 after purchasing an additional 86,208 shares in the last quarter. Finally, Baillie Gifford & Co. grew its stake in shares of Intuitive Surgical by 0.6% during the third quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider’s stock valued at $1,890,676,000 after purchasing an additional 24,183 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 270 shares of Intuitive Surgical stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $540.15, for a total transaction of $145,840.50. Following the completion of the transaction, the chief financial officer now directly owns 8,757 shares of the company’s stock, valued at $4,730,093.55. The trade was a 2.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mark Brosius sold 2,128 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total transaction of $1,095,920.00. Following the completion of the transaction, the senior vice president now directly owns 273 shares in the company, valued at $140,595. The trade was a 88.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,190 shares of company stock worth $25,012,927 over the last ninety days. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Trading Down 1.4 %

Shares of NASDAQ:ISRG traded down $7.72 during trading on Monday, hitting $539.75. 1,433,191 shares of the company’s stock traded hands, compared to its average volume of 1,351,010. The company has a 50-day moving average price of $535.93 and a 200-day moving average price of $495.17. Intuitive Surgical, Inc. has a 52 week low of $355.17 and a 52 week high of $556.23. The company has a market cap of $192.25 billion, a price-to-earnings ratio of 86.78, a price-to-earnings-growth ratio of 5.31 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.32. The company had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. On average, analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. The Goldman Sachs Group set a $604.00 price objective on shares of Intuitive Surgical in a research report on Friday, October 18th. Piper Sandler restated an “overweight” rating and set a $538.00 target price (up previously from $495.00) on shares of Intuitive Surgical in a research report on Friday, October 18th. Truist Financial raised their price target on Intuitive Surgical from $570.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Citigroup boosted their price objective on Intuitive Surgical from $567.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada raised their target price on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $554.17.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.